NRx Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
6.70 |
32.50 |
140.15 |
518.62 |
1,054.14 |
162.29 |
| Przychód Δ r/r |
0.00% |
385.07% |
331.23% |
270.05% |
103.26% |
-84.60% |
| Przychód (min) |
2.75 |
14.21 |
55.28 |
213.22 |
433.38 |
66.72 |
| Przychód (max) |
10.93 |
50.79 |
234.89 |
846.33 |
1,720.23 |
264.84 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-24.11 |
-1.36 |
7.33 |
19.00 |
107.13 |
31.97 |
| Zysk netto % |
-359.85% |
-4.20% |
5.23% |
3.66% |
10.16% |
19.70% |
| EPS (średnia) |
-1.91 |
-0.13 |
0.70 |
4.93 |
10.19 |
3.04 |
| Liczba analityków (Przychody) |
2 |
2 |
3 |
2 |
1 |
1 |
| Liczba analityków (EPS) |
2 |
1 |
2 |
1 |
1 |
1 |
| symbol |
NRXP |
NRXP |
NRXP |
NRXP |
NRXP |
NRXP |